Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms

Psychiatry Research

Volumn 218, Issue 1-2, 2014, Pages 219-224

  Edgar, Chris J ^a   Blaettler, Thomas ^b   Bugarski Kirola, Dragana ^b   Le Scouiller, Stephanie ^a   Garibaldi, George M ^b   Marder, Stephen R ^c  

^a ROCHE PRODUCTS LTD   (United Kingdom)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical trials; Negative symptom factor; Negative symptoms; NSFS; Outcome assessment; PANSS; Psychiatric rating scales

Indexed keywords

BITOPERTIN; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; (4-(3-FLUORO-5-TRIFLUOROMETHYLPYRIDIN-2-YL)PIPERAZIN-1-YL)(5-METHANESULFONYL-2-(2,2,2-TRIFLUORO-1-METHYLETHOXY)PHENYL)METHANONE; PIPERAZINE DERIVATIVE; SULFONE;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONSTRUCT VALIDITY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; INTERNAL CONSISTENCY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEGATIVE SYNDROME; OUTPATIENT; PERSONAL AND SOCIAL PERFORMANCE SCALE; PHASE 2 CLINICAL TRIAL; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SYMPTOM; TEST RETEST RELIABILITY; THOUGHT DISORDER; TREATMENT RESPONSE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; MIDDLE AGED; REPRODUCIBILITY; SYMPTOM ASSESSMENT; TREATMENT OUTCOME; VALIDATION STUDY;

ADULT; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SULFONES; SYMPTOM ASSESSMENT; TREATMENT OUTCOME;

EID: 84902119395     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2014.04.009     Document Type: Article

References (48)

1. Alphs L., Morlock R., Coon C., Cazorla P., Szegedi A., Panagides J. Validation of a 4-item Negative Symptom Assessment (NSA-4): a short, practical clinical tool for the assessment of negative symptoms in schizophrenia. International Journal of Methods in Psychiatric Research 2011, 20:e31-e37.
2. Arango C., Garibaldi G., Marder S.R. Pharmacological approaches to treating negative symptoms: a review of clinical trials. Schizophrenia Research 2013, 150:346-352.
3. Cazorla, P., Alphs, L., Hill, C., Stewart, M., Wilson, J., Morlock, R., Szegedi, A., 2008. Psychometric evaluation of the Negative Symptom Assessment (NSA-16) Scale in schizophrenic patients with predominant negative symptoms. In: Proceedings of the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders. Montreux, Switzerland.
4. Citrome L., Meng X., Hochfeld M. Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis. Schizophrenia Research 2011, 131:75-81.
5. Cronbach L.J. Coefficient alpha and the internal structure of tests. Psychometrika 1951, 16:297-334.
6. Daniel, D.G., 2013. Issues in selection of instruments to measure negative symptoms. Schizophrenia Research 150, 343-345.
7. Daniel D.G., Alphs L., Cazorla P., Bartko J.J., Panagides J. Training for assessment of negative symptoms of schizophrenia across languages and cultures: comparison of the NSA-16 with the PANSS Negative Subscale and Negative Symptom factor. Clinical Schizophrenia & Related Psychoses 2011, 5:87-94.
8. Gastpar M., Masiak M., Latif M.A., Frazzingaro S., Medori R., Lombertie E.R. Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine. Journal of Psychopharmacology 2005, 19:32-38.
9. Haro J.M., Kamath S.A., Ochoa S., Novick D., Rele K., Fargas A., Rodriguez M.J., Rele R., Orta J., Kharbeng A., Araya S., Gervin M., Alonso J., Mavreas V., Lavrentzou E., Liontos N., Gregor K., Jones P.B. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatrica Scandinavica. Supplementum 2003, s416:16-23.
10. Janicak P.G., Glick I.D., Marder S.R., Crandall D.T., McQuade R.D., Marcus R.N., Eudicone J.M., Assuncao-Talbott S. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. The Journal of Clinical Psychiatry 2009, 70:25-35.
11. Kay S.R. Positive-negative symptom assessment in schizophrenia: psychometric issues and scale comparison. The Psychiatric Quarterly 1990, 61:163-178.
12. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13:261-276.
13. Kay S.R., Opler L.A., Lindenmayer J.P. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Research 1988, 23:99-110.
14. Khan A., Lewis C., Lindenmayer J.P. Use of non-parametric item response theory to develop a shortened version of the Positive and Negative Syndrome Scale (PANSS). BMC Psychiatry 2011, 11:178.
15. Kirkpatrick B., Fischer B. Subdomains within the negative symptoms of schizophrenia: commentary. Schizophrenia Bulletin 2006, 32:246-249.
16. Kirkpatrick B., Fenton W.S., Carpenter W.T., Marder S.R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophrenia Bulletin. [Consensus Development Conference, NIH] 2006, 32(2):214-219.
17. Klingberg S., Wittorf A., Wiedemann G. Disorganization and cognitive impairment in schizophrenia: independent symptom dimensions?. European Archives of Psychiatry and Clinical Neuroscience 2006, 256:532-540.
18. Kurtz M.M., Moberg P.J., Ragland J.D., Gur R.C., Gur R.E. Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: a 1- and 4-year prospective study. Schizophrenia Bulletin 2005, 31:167-174.
19. Lancon C., Auquier P., Nayt G., Reine G. Stability of the five-factor structure of the Positive and Negative Syndrome Scale (PANSS). Schizophrenia Research 2000, 42:231-239.
20. Lasser R., Bossie C.A., Gharabawi G., Eerdekens M., Nasrallah H.A. Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder. Journal of Affective Disorders 2004, 83:263-275.
21. Lasser R.A., Bossie C.A., Zhu Y., Gharabawi G., Eerdekens M., Davidson M. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder. International Journal of Geriatric Psychiatry 2004, 19:898-905.
22. Lee K.H., Harris A.W., Loughland C.M., Williams L.M. The five symptom dimensions and depression in schizophrenia. Psychopathology 2003, 36:226-233.
23. Leucht S., Davis J.M., Engel R.R., Kissling W., Kane J.M. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatrica Scandinavica. Supplementum 2009, 7-14.
24. Levine S.Z., Leucht S. Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. Biological Psychiatry 2010, 68:86-92.
25. Levine S.Z., Leucht S. Identifying clinically meaningful symptom response cut-off values on the SANS in predominant negative symptoms. Schizophrenia Research 2013, 145:125-127.
26. Levine S.Z., Rabinowitz J. Revisiting the 5 dimensions of the Positive and Negative Syndrome Scale. Journal of Clinical Psychopharmacology 2007, 27:431-436.
27. Levine S.Z., Rabinowitz J., Rizopoulos D. Recommendations to improve the positive and negative syndrome scale (PANSS) based on item response theory. Psychiatry Research 2011, 188:446-452.
28. Llorca P.M., Bouhours P., Moreau-Mallet V. Improved symptom control, functioning and satisfaction in French patients treated with long-acting injectable risperidone. L[U+05F3]Encephale 2008, 34:170-178.
29. Lysaker P.H., Davis L.W. Social function in schizophrenia and schizoaffective disorder: associations with personality, symptoms and neurocognition. Health and Quality of Life Outcomes 2004, 2:15.
30. Lysaker P.H., Lancaster R.S., Nees M.A., Davis L.W. Attributional style and symptoms as predictors of social function in schizophrenia. Journal of Rehabilitation Research and Development 2004, 41:225-232.
31. Marder S.R., Alphs L., Anghelescu I.G., Arango C., Barnes T.R., Caers I., Daniel D.G., Dunayevich E., Fleischhacker W.W., Garibaldi G., Green M.F., Harvey P.D., Kahn R.S., Kane J.M., Keefe R.S., Kinon B., Leucht S., Lindenmayer J.P., Malhotra A.K., Stauffer V., Umbricht D., Wesnes K., Kapur S., Rabinowitz J. Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophrenia Research 2013, 150:328-333.
32. Marder S.R., Davis J.M., Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. The Journal of Clinical Psychiatry 1997, 58:538-546.
33. Marder S.R., Rabinowitz J., Kapur S. Clinical trials for negative symptoms-emerging directions and unresolved issues. Schizophrenia Research 2013, 150:327.
34. Milev P., Ho B.C., Arndt S., Andreasen N.C. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. The American Journal of Psychiatry 2005, 162:495-506.
35. Mohr P.E., Cheng C.M., Claxton K., Conley R.R., Feldman J.J., Hargreaves W.A., Lehman A.F., Lenert L.A., Mahmoud R., Marder S.R., Neumann P.J. The heterogeneity of schizophrenia in disease states. Schizophrenia Research 2004, 71:83-95.
36. Muller M.J., Wetzel H. Improvement of inter-rater reliability of PANSS items and subscales by a standardized rater training. Acta Psychiatrica Scandinavica 1998, 98:135-139.
37. Nasrallah H., Morosini P., Gagnon D.D. Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia. Psychiatry Research 2008, 161:213-224.
38. Nasrallah H.A., Gopal S., Gassmann-Mayer C., Quiroz J.A., Lim P., Eerdekens M., Yuen E., Hough D. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 2010, 35:2072-2082.
39. Norman R.M., Malla A.K., McLean T., Voruganti L.P., Cortese L., McIntosh E., Cheng S., Rickwood A. The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale. Acta Psychiatrica Scandinavica 2000, 102:303-309.
40. Nunnally J.C., Bernstein I.H. Psychometric Theory 1994, McGraw-Hill, New York. 3rd ed.
41. Shrout P.E., Fleiss J.L. Intraclass correlations: uses in assessing rater reliability. Psychological Bulletin 1979, 86:420-428.
42. Tavakol M., Dennick R. Making sense of Cronbach[U+05F3]s alpha. International Journal of Medical Education 2011, 53-55.
43. Umbricht D., Martin-Facklam M., Pizzagalli F., Youssef E., Yoo K., Dorflinger E., Bausch A., Arrowsmith R., Alberati D., Santarelli L. Glycine transporter type 1 (Glyt1) inhibitor RG1678: results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia. Schizophrenia Bulletin 2011, 37(Suppl. 1:324):1-327.
44. Velligan D.I., Mahurin R.K., Diamond P.L., Hazleton B.C., Eckert S.L., Miller A.L. The functional significance of symptomatology and cognitive function in schizophrenia. Schizophrenia Research 1997, 25:21-31.
45. Wallwork R.S., Fortgang R., Hashimoto R., Weinberger D.R., Dickinson D. Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophrenia Research 2012, 137:246-250.
46. Wang X., Savage R., Borisov A., Rosenberg J., Woolwine B., Tucker M., May R., Feldman J., Nemeroff C.B., Miller A.H. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study. Journal of Psychiatric Research 2006, 40:669-676.
47. Wilkinson G., Hesdon B., Wild D., Cookson R., Farina C., Sharma V., Fitzpatrick R., Jenkinson C. Self-report quality of life measure for people with schizophrenia: the SQLS. The British Journal of Psychiatry: The Journal of Mental Science 2000, 177:42-46.
48. Wolthaus J.E., Dingemans P.M., Schene A.H., Linszen D.H., Knegtering H., Holthausen E.A., Cahn W., Hijman R. Component structure of the Positive and Negative Syndrome Scale (PANSS) in patients with recent-onset schizophrenia and spectrum disorders. Psychopharmacology 2000, 150:399-403.